Methods for screening, predicting and monitoring prostate cancer

• US 9,952,221 B2
• Filed: 06/29/2015
• Issued: 04/24/2018
• Est. Priority Date: 01/24/2001
• Status: Active Grant

• Current Assignee: Health Discovery Corporation
• Original Assignee: Health Discovery Corporation
• Inventors: Guyon, Isabelle
• Primary Examiner(s): Reddig, Peter J
• Application Number:
  US14/754,434
• Publication Number:
  US 20150339448A1
• Time in Patent Office: 1,030 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

Biomarkers are identified by analyzing gene expression data using support vector machines (SVM) to rank genes according to their ability to separate prostate cancer from normal tissue. Expression products of identified genes are detected in patient samples, including prostate tissue, serum, semen and urine, to screen, predict and monitor prostate cancer.

Claims

1. A computer-based method for screening a male human subject for the presence of and treating prostate cancer, comprising:

screening the subject by;

obtaining a biological sample from the subject;

detecting a plurality of relative expression values within the biological sample for each of a group of polynucleotides comprising nucleic acids 1 through 498 of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 5, relative to one or more reference genes;

performing a diagnostic procedure comprising;

downloading the plurality of expression values into a computer processor;

calculating within the computer processor a prediction score S according to the relationship S=ln(HSPD1/ref.gene)+ln(IMPDH2/ref.gene)+ln(PDLIM5/ref.gene)+ln(UAP1/ref.gene)+b, where ref.gene is the one or more reference gene and b is a bias value, wherein b is adjusted to compensate for reduced expression level in the biological sample and b is further adjusted to obtain a selected sensitivity and a selected specificity;

administering an effective anti-cancer treatment to the subject.

2. The method of claim 1, further comprising generating an estimate of a probability P that the biological sample is cancerous according to the relationship

P(cancer)=1/(1+exp(−

aS)), where a is a scaling factor.

3. The method of claim 1, wherein the selected sensitivity and the selected specificity are each greater than 90%.

4. The method of claim 1, wherein the relative expression values are detected within the biological sample using RT-PCR.

5. The method of claim 1, wherein the biological sample comprises urine.

6. The method of claim 1, wherein the one or more reference genes comprises B2M.

7. The method of claim 1, wherein the one or more reference genes comprises KLK3.

8. A computer-based method for screening a male human subject for and treating prostate cancer, comprising:

obtaining a biological sample from the subject;

detecting values corresponding to relative expression products values within the biological sample for at least each polynucleotide of a group of polynucleotides comprising nucleic acids 1 through 498 of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 5, relative to one or more reference genes;

downloading the plurality of expression values into a computer processor;

calculating within the computer processor a prediction score S according to the relationship S=ln(HSPD1/ref.gene)+ln(IMPDH2/ref.gene)+ln(PDLIM5/ref.gene)+ln(UAP1/ref.gene)+b, where ref.gene is the one or more reference gene and b is a bias value, wherein b is adjusted to compensate for reduced expression level in the biological sample and b is further adjusted to obtain a sensitivity and a specificity each greater than 90%;

and

administering an effective anti-cancer treatment to the subject.

9. The method of claim 8, further comprising generating an estimate of a probability P that the biological sample is cancerous according to the relationship

P(cancer)=1/(1+exp(−

aS)), where a is a scaling factor.

10. The method of claim 8, wherein the relative expression values are detected within the biological sample using RT-PCR.

11. The method of claim 8, wherein the biological sample comprises urine.

12. The method of claim 8, wherein the one or more reference genes comprises B2M.

13. The method of claim 8, wherein the one or more reference genes comprises KLK3.